Global Mitral Valve Disease Market Size Study & Forecast, by Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), by Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regu

Global Mitral Valve Disease Market Size Study & Forecast, by Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), by Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Regional Analysis, 2023-2030

Global Mitral Valve Disease Market is valued at approximately USD 2.72 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.8% over the forecast period 2023-2030. Mitral valve disease refers to a medical condition that affects the mitral valve, which is one of the heart's four valves responsible for regulating blood flow between the left atrium and left ventricle. The disease encompasses various abnormalities of the mitral valve, including mitral regurgitation, mitral stenosis, and mitral valve prolapse. The market for mitral valve treatment is experiencing growth due to factors such as the rising awareness among individuals about mitral valve disease, the increasing prevalence of risk factors such as high blood pressure, high cholesterol, and changes in lifestyle habits. These factors collectively contribute to the growing demand for mitral valve treatment products and drive the overall market growth across the globe

The increasing prevalence of Mitral regurgitation (MR) is primarily driving the expansion of the mitral valve disease market. As per the National Institutes of Health report released in 2021, mitral regurgitation (MR) holds the distinction of being the most prevalent valvular abnormality on a global scale. It impacts more than 2% of the entire population and exhibits a prevalence that rises with advancing age. The market growth is further propelled by the increasing demand for minimally invasive procedures to treat mitral valve diseases, as well as the subsequent advancements and development of minimally invasive products in this field. However, the growth of the market for mitral valve disease is hindered by the substantial costs associated with the repair and replacement surgeries procedures of the mitral valve, as well as the stringent regulations imposed by governing bodies for the development, usage, and approval of mitral heart valves and medications throughout the forecast period of 2023-2030.

The key regions considered for the Global Mitral Valve Disease Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of well-developed healthcare infrastructure, higher consumer awareness regarding mitral valve diseases, the presence of major players in the United States, and a wide range of offerings in the mitral valve treatment sector. Asia Pacific is expected to fastest growing region during the forecast period, owing to factors such as the large population base and the rising healthcare expenditure in countries such as China and India.

Major market players included in this report are:
Teva Pharmaceutical Industries Ltd.
Corcym UK Limited
Abbott Laboratories
Zydus Lifesciences Limited
Medtronic plc
Edwards Lifesciences Corporation
Affluent Medical
ShockWave Medical, Inc.
Valcare Medical
Pfizer Inc.

Recent Developments in the Market:
In November 2021, Medtronic plc. released preliminary data on the Intrepid transcatheter mitral valve replacement (TMVR) system, which was used in patients with severe and symptomatic mitral valve regurgitation (MR) through the transfemoral access route. The data from the initial five patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System demonstrated a 100% survival rate with no reported strokes.

In June 2021, Gyrus Capital acquired LivaNova Plc.'s heart valve company and formed a new global medical device company named it as Corcym. This independent company aims to focus on delivering optimal solutions to combat structural heart disease for patients and heart surgeons.

Global Mitral Valve Disease Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Indication, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Mitral Valve Repair
Mitral Valve Replacement
Cardiac Resynchronization Therapy
Mitral Valve Therapeutics

By Indication:
Mitral Valve Stenosis
Mitral Valve Prolapse
Mitral Valve Regurgitation

By End User:
Hospitals
Ambulatory Surgical Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Teva Pharmaceutical Industries Ltd.
Corcym UK Limited
Abbott Laboratories
Zydus Lifesciences Limited
Medtronic plc
Edwards Lifesciences Corporation
Affluent Medical
ShockWave Medical, Inc.
Valcare Medical
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.